|
US5206344A
(en)
*
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
CA1283046C
(en)
*
|
1986-05-29 |
1991-04-16 |
Nandini Katre |
Tumor necrosis factor formulation
|
|
US4745180A
(en)
*
|
1986-06-27 |
1988-05-17 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using heparin fragments
|
|
US5004605A
(en)
*
|
1987-12-10 |
1991-04-02 |
Cetus Corporation |
Low pH pharmaceutical compositions of recombinant β-interferon
|
|
US4847325A
(en)
*
|
1988-01-20 |
1989-07-11 |
Cetus Corporation |
Conjugation of polymer to colony stimulating factor-1
|
|
IE62463B1
(en)
*
|
1988-07-07 |
1995-02-08 |
Res Dev Foundation |
Immunoconjugates for cancer diagnosis and therapy
|
|
US5091176A
(en)
*
|
1988-11-02 |
1992-02-25 |
W. R. Grace & Co.-Conn. |
Polymer-modified peptide drugs having enhanced biological and pharmacological activities
|
|
CA2006596C
(en)
*
|
1988-12-22 |
2000-09-05 |
Rika Ishikawa |
Chemically-modified g-csf
|
|
US6166183A
(en)
*
|
1992-11-30 |
2000-12-26 |
Kirin-Amgen, Inc. |
Chemically-modified G-CSF
|
|
US4902502A
(en)
*
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
US5166322A
(en)
*
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
|
WO1990015628A1
(en)
*
|
1989-06-14 |
1990-12-27 |
Cetus Corporation |
Polymer/antibiotic conjugate
|
|
KR920703114A
(ko)
*
|
1989-07-14 |
1992-12-17 |
원본미기재 |
접합체 백신을 위한 시토킨 및 호르몬 운반체
|
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
Method for the production of a human recombinant tumor necrosis factor inhibitor
|
|
WO1991001758A1
(en)
*
|
1989-08-07 |
1991-02-21 |
Debiopharm S.A. |
Biologically active drug polymer derivatives
|
|
US5393735A
(en)
*
|
1990-08-09 |
1995-02-28 |
Rohm And Haas Company |
Herbicidal glutarimides
|
|
US5552391A
(en)
*
|
1990-01-16 |
1996-09-03 |
La Jolla Pharmaceutical Company |
Chemically-defined non-polymeric valency platform molecules and conjugates thereof
|
|
JPH04218000A
(ja)
*
|
1990-02-13 |
1992-08-07 |
Kirin Amgen Inc |
修飾ポリペプチド
|
|
FR2658519B1
(fr)
*
|
1990-02-19 |
1995-07-07 |
Serbio |
Substrats peptidiques pour identification du facteur xa.
|
|
FR2658521B1
(fr)
*
|
1990-02-19 |
1994-01-21 |
Serbioo |
Bipeptides symetriques comportant un reste polyalkyleneglycol, procede de preparation et utilisation dans le dosage des proteases.
|
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
|
US5312903A
(en)
*
|
1990-06-01 |
1994-05-17 |
E. I. Du Pont De Nemours And Company |
Lysine-glycosylated recombinant interleukin-2
|
|
IE912365A1
(en)
*
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
|
US5229366A
(en)
*
|
1990-10-23 |
1993-07-20 |
Fuji Photo Film Co., Ltd. |
Peptide-containing polyethylene glycol derivatives and application thereof
|
|
US5595732A
(en)
*
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
|
US5382657A
(en)
*
|
1992-08-26 |
1995-01-17 |
Hoffmann-La Roche Inc. |
Peg-interferon conjugates
|
|
KR100361933B1
(ko)
|
1993-09-08 |
2003-02-14 |
라 졸라 파마슈티칼 컴파니 |
화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
|
|
ATE359830T1
(de)
*
|
1993-09-08 |
2007-05-15 |
Jolla Pharma |
Chemisch definierten nicht-polymer wertigen plattformmolokülen und ihren konjugaten
|
|
US5880131A
(en)
*
|
1993-10-20 |
1999-03-09 |
Enzon, Inc. |
High molecular weight polymer-based prodrugs
|
|
US5446090A
(en)
*
|
1993-11-12 |
1995-08-29 |
Shearwater Polymers, Inc. |
Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
|
|
US5629384A
(en)
*
|
1994-05-17 |
1997-05-13 |
Consiglio Nazionale Delle Ricerche |
Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
|
|
US20030053982A1
(en)
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
|
ATE452136T1
(de)
*
|
1995-05-04 |
2010-01-15 |
Gilead Sciences Inc |
Nukleinsäureligand-komplexe
|
|
US8071737B2
(en)
|
1995-05-04 |
2011-12-06 |
Glead Sciences, Inc. |
Nucleic acid ligand complexes
|
|
US5874409A
(en)
|
1995-06-07 |
1999-02-23 |
La Jolla Pharmaceutical Company |
APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
|
|
WO1997009989A1
(en)
*
|
1995-09-14 |
1997-03-20 |
Lxr Biotechnology Inc. |
Compositions with anti-apoptotic activity, containing a mixture of phospholipids
|
|
TW517067B
(en)
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
|
CN1168495C
(zh)
*
|
1997-01-15 |
2004-09-29 |
凤凰药理学公司 |
被修饰的肿瘤坏死因子
|
|
US6321909B1
(en)
|
1997-02-13 |
2001-11-27 |
Sky High, Llc |
System for storing polyethylene glycol solutions
|
|
JP4574007B2
(ja)
*
|
1998-04-28 |
2010-11-04 |
メルク・セローノ・ソシエテ・アノニム |
ポリオール−ifn−ベータ複体
|
|
US6858210B1
(en)
|
1998-06-09 |
2005-02-22 |
La Jolla Pharmaceutical Co. |
Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
|
|
US6783965B1
(en)
|
2000-02-10 |
2004-08-31 |
Mountain View Pharmaceuticals, Inc. |
Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
|
|
ATE498409T1
(de)
|
1998-08-06 |
2011-03-15 |
Mountain View Pharmaceuticals |
Peg-uricase konjugate und verwendung davon
|
|
MXPA01003790A
(es)
|
1998-10-16 |
2002-09-18 |
Biogen Inc |
Proteinas de fusion beta - interferon y sus usos.
|
|
HU229888B1
(en)
*
|
1998-10-16 |
2014-11-28 |
Biogen Idec Ma Inc Cambridge |
Polymer conjugates of interferon betha-1a and uses
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6458953B1
(en)
|
1998-12-09 |
2002-10-01 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising carbamate linkages
|
|
US6399578B1
(en)
|
1998-12-09 |
2002-06-04 |
La Jolla Pharmaceutical Company |
Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
|
|
US7431921B2
(en)
|
1999-08-27 |
2008-10-07 |
Maxygen Aps |
Interferon beta-like molecules
|
|
BR0013638A
(pt)
*
|
1999-08-27 |
2002-05-14 |
Maxygen Aps |
Novas moléculas semelhantes a interferon beta
|
|
US6531122B1
(en)
|
1999-08-27 |
2003-03-11 |
Maxygen Aps |
Interferon-β variants and conjugates
|
|
US7144574B2
(en)
|
1999-08-27 |
2006-12-05 |
Maxygen Aps |
Interferon β variants and conjugates
|
|
TR200101086A3
(OSRAM)
*
|
1999-10-15 |
2001-08-21 |
|
|
|
PL356007A1
(en)
|
1999-11-12 |
2004-05-31 |
Maxygen Holdings Ltd |
Interferon gamma conjugates
|
|
US7230081B1
(en)
|
1999-11-12 |
2007-06-12 |
Maxygen Holdings, Ltd. |
Interferon gamma conjugates
|
|
AR027509A1
(es)
|
2000-01-10 |
2003-04-02 |
Maxygen Aps |
Conjugados g-csf
|
|
JP2003521930A
(ja)
|
2000-02-11 |
2003-07-22 |
マキシゲン・エイピーエス |
第VII因子または第VIIa因子様分子
|
|
CA2414076A1
(en)
|
2000-06-08 |
2001-12-13 |
La Jolla Pharmaceutical Company |
Multivalent platform molecules comprising high molecular weight polyethylene oxide
|
|
ZA200305980B
(en)
|
2001-02-12 |
2007-01-31 |
Res Dev Foundation |
Modified proteins, designer toxins, and methods of making thereof
|
|
ATE432288T1
(de)
|
2001-02-27 |
2009-06-15 |
Maxygen Aps |
Neue interferon-beta-ähnliche moleküle
|
|
US7038015B2
(en)
|
2001-04-06 |
2006-05-02 |
Maxygen Holdings, Ltd. |
Interferon gamma polypeptide variants
|
|
US6958388B2
(en)
|
2001-04-06 |
2005-10-25 |
Maxygen, Aps |
Interferon gamma polypeptide variants
|
|
WO2003000278A1
(en)
*
|
2001-06-22 |
2003-01-03 |
Kyowa Hakko Kogyo Co., Ltd. |
Ointments
|
|
EP1414471B1
(en)
|
2001-07-17 |
2012-06-13 |
Research Development Foundation |
Therapeutic agents comprising pro-apoptotic proteins
|
|
JP2005507870A
(ja)
|
2001-08-13 |
2005-03-24 |
ユニバーシティ・オブ・サザン・カリフォルニア |
低毒性のインターロイキン−2突然変異体
|
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
|
US7265084B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
US7399613B2
(en)
|
2001-10-10 |
2008-07-15 |
Neose Technologies, Inc. |
Sialic acid nucleotide sugars
|
|
ES2411007T3
(es)
|
2001-10-10 |
2013-07-04 |
Novo Nordisk A/S |
Remodelación y glicoconjugación de péptidos
|
|
US7297511B2
(en)
|
2001-10-10 |
2007-11-20 |
Neose Technologies, Inc. |
Interferon alpha: remodeling and glycoconjugation of interferon alpha
|
|
US7179617B2
(en)
|
2001-10-10 |
2007-02-20 |
Neose Technologies, Inc. |
Factor IX: remolding and glycoconjugation of Factor IX
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US7696163B2
(en)
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US7226903B2
(en)
|
2001-10-10 |
2007-06-05 |
Neose Technologies, Inc. |
Interferon beta: remodeling and glycoconjugation of interferon beta
|
|
US7265085B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycoconjugation methods and proteins/peptides produced by the methods
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
|
US7439043B2
(en)
|
2001-10-10 |
2008-10-21 |
Neose Technologies, Inc. |
Galactosyl nucleotide sugars
|
|
US7473680B2
(en)
|
2001-11-28 |
2009-01-06 |
Neose Technologies, Inc. |
Remodeling and glycoconjugation of peptides
|
|
CA2753899C
(en)
|
2002-01-18 |
2014-03-25 |
Biogen Idec Ma Inc. |
Polyalkylene glycol with moiety for conjugating biologically active compounds
|
|
PT1517710E
(pt)
|
2002-06-21 |
2011-07-08 |
Novo Nordisk Healthcare Ag |
Glicoformas do factor vii peguilado
|
|
US7524931B2
(en)
|
2002-07-03 |
2009-04-28 |
Maxygen Holdings Ltd. |
Full-length interferon gamma polypeptide variants
|
|
CN102319437B
(zh)
|
2002-12-26 |
2017-10-13 |
山景医药公司 |
具有增强的生物学效用的干扰素‑β的聚合物缀合物
|
|
CA2519092C
(en)
|
2003-03-14 |
2014-08-05 |
Neose Technologies, Inc. |
Branched water-soluble polymers and their conjugates
|
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
EP1613261A4
(en)
|
2003-04-09 |
2011-01-26 |
Novo Nordisk As |
INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
|
|
PL1615945T3
(pl)
|
2003-04-09 |
2012-03-30 |
Ratiopharm Gmbh |
Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
|
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
|
DK1668031T3
(da)
*
|
2003-08-07 |
2008-06-30 |
Zymogenetics Inc |
Homogene præparater af IL-29
|
|
PL1666496T3
(pl)
*
|
2003-08-25 |
2014-08-29 |
Toray Industries |
Kompozyt interferonu beta
|
|
CN102516386A
(zh)
|
2003-10-10 |
2012-06-27 |
诺沃挪第克公司 |
Il-21衍生物
|
|
EP2633866A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
|
KR20060120141A
(ko)
|
2003-11-24 |
2006-11-24 |
네오스 테크놀로지스, 인크. |
글리코페질화 에리트로포이에틴
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
WO2005074546A2
(en)
|
2004-02-02 |
2005-08-18 |
Ambrx, Inc. |
Modified human growth hormone polypeptides and their uses
|
|
CA2565414A1
(en)
|
2004-05-04 |
2005-11-24 |
Novo Nordisk Health Care Ag |
O-linked glycoforms of polypeptides and method to manufacture them
|
|
NZ582684A
(en)
|
2004-06-18 |
2011-05-27 |
Ambrx Inc |
Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker
|
|
EP1771066A2
(en)
|
2004-07-13 |
2007-04-11 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
|
|
JP2008507280A
(ja)
|
2004-07-21 |
2008-03-13 |
アンブレツクス・インコーポレイテツド |
非天然コードアミノ酸を用いた生合成ポリペプチド
|
|
US8268967B2
(en)
|
2004-09-10 |
2012-09-18 |
Novo Nordisk A/S |
Glycopegylated interferon α
|
|
DK2586456T3
(en)
|
2004-10-29 |
2016-03-21 |
Ratiopharm Gmbh |
Conversion and glycopegylation of fibroblast growth factor (FGF)
|
|
KR20070090023A
(ko)
|
2004-12-22 |
2007-09-04 |
암브룩스, 인코포레이티드 |
변형 인간 성장 호르몬
|
|
WO2006074467A2
(en)
|
2005-01-10 |
2006-07-13 |
Neose Technologies, Inc. |
Glycopegylated granulocyte colony stimulating factor
|
|
US20070154992A1
(en)
|
2005-04-08 |
2007-07-05 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
|
NZ562292A
(en)
|
2005-04-11 |
2009-11-27 |
Savient Pharmaceuticals Inc |
Variant forms of urate oxidase and use thereof
|
|
JP5216580B2
(ja)
|
2005-05-25 |
2013-06-19 |
ノヴォ ノルディスク アー/エス |
グリコペグ化第ix因子
|
|
ES2553160T3
(es)
|
2005-06-17 |
2015-12-04 |
Novo Nordisk Health Care Ag |
Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
|
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
|
EP1951890A4
(en)
|
2005-11-16 |
2009-06-24 |
Ambrx Inc |
PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
|
|
RU2304586C1
(ru)
*
|
2006-03-27 |
2007-08-20 |
Михаил Николаевич Смирнов |
Препарат интерлейкина-2 и способ его получения
|
|
RU2322452C2
(ru)
*
|
2006-03-27 |
2008-04-20 |
Михаил Николаевич Смирнов |
Иммуномодулирующая композиция
|
|
EP2213733A3
(en)
|
2006-05-24 |
2010-12-29 |
Novo Nordisk Health Care AG |
Factor IX analogues having prolonged in vivo half life
|
|
CN101516388B
(zh)
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
通过o-联糖基化序列的肽的糖基化
|
|
CN104193815A
(zh)
|
2006-09-08 |
2014-12-10 |
Ambrx公司 |
经修饰的人类血浆多肽或Fc骨架和其用途
|
|
WO2008031612A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Creabilis Therapeutics S.P.A. |
Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
|
|
EP2054521A4
(en)
|
2006-10-03 |
2012-12-19 |
Novo Nordisk As |
PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
|
|
KR20140012199A
(ko)
|
2007-03-30 |
2014-01-29 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
|
JP2010523582A
(ja)
|
2007-04-03 |
2010-07-15 |
バイオジェネリクス アクチェンゲゼルシャフト |
グリコpeg化g−csfを用いた治療方法
|
|
WO2008154639A2
(en)
|
2007-06-12 |
2008-12-18 |
Neose Technologies, Inc. |
Improved process for the production of nucleotide sugars
|
|
NZ583276A
(en)
|
2007-08-27 |
2012-06-29 |
Biogenerix Ag |
Liquid formulations of granulocyte colony stimulating factor and polymer conjugates
|
|
EP2930182A1
(en)
|
2007-11-20 |
2015-10-14 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
|
JP2011510005A
(ja)
*
|
2008-01-18 |
2011-03-31 |
ダウ グローバル テクノロジーズ インコーポレイティド |
メトキシポリエチレングリコールを用いる難溶性活性物質の水溶解度増強方法
|
|
NZ601868A
(en)
|
2008-01-22 |
2014-05-30 |
Araim Pharmaceuticals Inc |
Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
|
|
EP3103880A1
(en)
|
2008-02-08 |
2016-12-14 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
|
RU2573587C2
(ru)
|
2008-02-27 |
2016-01-20 |
Ново Нордиск А/С |
Конъюгированные молекулы фактора viii
|
|
JP5592355B2
(ja)
|
2008-05-13 |
2014-09-17 |
アドヴァンスト リキッド ロジック インコーポレイテッド |
液滴アクチュエータ装置、システム、および方法
|
|
AU2009274076C1
(en)
|
2008-07-23 |
2014-04-17 |
Ambrx, Inc. |
Modified bovine G-CSF polypeptides and their uses
|
|
US9121024B2
(en)
|
2008-09-26 |
2015-09-01 |
Ambrx, Inc. |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
|
PL2342223T3
(pl)
|
2008-09-26 |
2017-09-29 |
Ambrx, Inc. |
Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
|
|
KR101861547B1
(ko)
|
2009-06-25 |
2018-07-02 |
크레알타 파마슈티칼스 엘엘씨 |
페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체매개 상실을 예측하는 방법 및 키트
|
|
WO2011087810A1
(en)
|
2009-12-21 |
2011-07-21 |
Ambrx, Inc. |
Modified porcine somatotropin polypeptides and their uses
|
|
BR112012015461A2
(pt)
|
2009-12-21 |
2017-01-10 |
Ambrx Inc |
polipeptídeos de somatotropina boviina modificados e seus usos
|
|
EP2542569B1
(en)
|
2010-03-05 |
2020-09-16 |
Omeros Corporation |
Chimeric inhibitor molecules of complement activation
|
|
EP2569331A1
(en)
|
2010-05-10 |
2013-03-20 |
Perseid Therapeutics LLC |
Polypeptide inhibitors of vla4
|
|
ES2742296T3
(es)
|
2010-08-17 |
2020-02-13 |
Ambrx Inc |
Polipéptidos de relaxina modificados y sus usos
|
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
|
KR20200070407A
(ko)
*
|
2010-11-12 |
2020-06-17 |
넥타르 테라퓨틱스 |
Il-2 부분 및 중합체의 접합체
|
|
EP2673294B1
(en)
|
2011-02-10 |
2016-04-27 |
Roche Glycart AG |
Mutant interleukin-2 polypeptides
|
|
AU2012280474A1
(en)
|
2011-07-01 |
2014-01-16 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
|
CN104136038A
(zh)
|
2012-02-29 |
2014-11-05 |
东丽株式会社 |
体腔积液抑制剂
|
|
WO2013156488A2
(en)
|
2012-04-16 |
2013-10-24 |
Leverton Licence Holdings Limited |
Optimised subcutaneous therapeutic agents
|
|
WO2013177187A2
(en)
*
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
|
DK2859017T3
(da)
|
2012-06-08 |
2019-05-13 |
Sutro Biopharma Inc |
Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
|
|
ES2611788T3
(es)
|
2012-06-26 |
2017-05-10 |
Sutro Biopharma, Inc. |
Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
|
|
EP3584255B1
(en)
|
2012-08-31 |
2022-02-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
|
US20150017120A1
(en)
*
|
2013-06-13 |
2015-01-15 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
|
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
|
WO2015054658A1
(en)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
|
CN107108710B
(zh)
|
2014-10-24 |
2022-02-15 |
百时美施贵宝公司 |
修饰的fgf-21多肽及其用途
|
|
MA47290A
(fr)
|
2015-10-08 |
2019-11-27 |
Nektar Therapeutics |
Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée
|
|
CN109310741A
(zh)
|
2016-04-29 |
2019-02-05 |
阿拉伊姆药品公司 |
用于预防和治疗与组织损伤相关的疾病和障碍的组织保护肽
|
|
US20200237881A1
(en)
|
2019-01-30 |
2020-07-30 |
Horizon Pharma Rheumatology Llc |
Reducing immunogenicity to pegloticase
|
|
EP3538135A4
(en)
|
2016-11-11 |
2020-07-29 |
Horizon Pharma Rheumatology LLC |
POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES
|
|
KR102670432B1
(ko)
|
2017-02-08 |
2024-05-28 |
브리스톨-마이어스 스큅 컴퍼니 |
약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도
|
|
EP3606947B1
(en)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
|
MX2019011770A
(es)
|
2017-04-03 |
2020-01-09 |
Hoffmann La Roche |
Inmunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15.
|
|
AU2018394189B2
(en)
*
|
2017-12-27 |
2023-12-21 |
Kyowa Kirin Co., Ltd. |
IL-2 variant
|
|
JP7441826B2
(ja)
|
2018-09-11 |
2024-03-01 |
アンブルックス,インコーポレイテッド |
インターロイキン-2ポリペプチド抱合物およびその使用
|
|
WO2020082057A1
(en)
|
2018-10-19 |
2020-04-23 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
|
WO2020158690A1
(ja)
|
2019-01-28 |
2020-08-06 |
東レ株式会社 |
肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体
|
|
JPWO2020158691A1
(ja)
|
2019-01-28 |
2021-12-02 |
東レ株式会社 |
肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体
|
|
CN119455003A
(zh)
|
2019-02-12 |
2025-02-18 |
Ambrx公司 |
包含抗体-tlr激动剂缀合物的组合物、方法和用途
|
|
JP2022538139A
(ja)
|
2019-07-02 |
2022-08-31 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
変異体インターロイキン-2及び抗cd8抗体を含む免疫複合体
|
|
IL321567A
(en)
*
|
2019-12-13 |
2025-08-01 |
Synthekine Inc |
Il-2 orthologs and methods of use
|
|
CN115243726B
(zh)
|
2020-03-11 |
2025-07-15 |
北京泰德制药股份有限公司 |
白介素-2多肽偶联物及其使用方法
|
|
CN115485028A
(zh)
|
2020-04-15 |
2022-12-16 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
|
KR20230010240A
(ko)
|
2020-05-11 |
2023-01-18 |
에프. 호프만-라 로슈 아게 |
변형된 pbmc 및 면역접합체를 이용한 병용 요법
|
|
AU2021327396A1
(en)
|
2020-08-20 |
2023-03-23 |
Ambrx, Inc. |
Antibody-TLR agonist conjugates, methods and uses thereof
|
|
CA3197740A1
(en)
|
2020-12-04 |
2022-06-09 |
F. Hoffman-La Roche Ag |
Ph-dependent mutant interleukin-2 polypeptides
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
MX2023011480A
(es)
|
2021-04-03 |
2023-12-06 |
Ambrx Inc |
Conjugados anticuerpo anti-her2-fármaco y usos de estos.
|
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
|
JP2024537096A
(ja)
|
2021-10-14 |
2024-10-10 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための代替的なPD1-IL7vイムノコンジュゲート
|
|
AU2022362681A1
(en)
|
2021-10-14 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
|
CN120676957A
(zh)
|
2023-01-20 |
2025-09-19 |
豪夫迈·罗氏有限公司 |
重组Fc结构域-IL2变体多肽以及与膜锚定抗原结合多肽的组合疗法
|
|
US12269875B2
(en)
|
2023-08-03 |
2025-04-08 |
Jeff R. Peterson |
Gout flare prevention methods using IL-1BETA blockers
|
|
WO2025163581A1
(en)
|
2024-02-01 |
2025-08-07 |
Astrazeneca Ab |
Cd8-binding cytokine engagers and methods of use thereof
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|